Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing
Meixian Jin,Xiao Yi,Wei Liao,Qi Chen,Wanren Yang,Yang Li,Shao Li,Yi Gao,Qing Peng,Shuqin Zhou
DOI: https://doi.org/10.1186/s13287-021-02152-9
2021-01-25
Abstract:Abstract Drug-induced liver injury (DILI) is one of the leading causes of clinical trial failures and high drug attrition rates. Currently, the commonly used hepatocyte models include primary human hepatocytes (PHHs), animal models, and hepatic cell lines. However, these models have disadvantages that include species-specific differences or inconvenient cell extraction methods. Therefore, a novel, inexpensive, efficient, and accurate model that can be applied to drug screening is urgently needed. Owing to their self-renewable ability, source abundance, and multipotent competence, stem cells are stable sources of drug hepatotoxicity screening models. Because 3D culture can mimic the in vivo microenvironment more accurately than can 2D culture, the former is commonly used for hepatocyte culture and drug screening. In this review, we introduce the different sources of stem cells used to generate hepatocyte-like cells and the models for hepatotoxicity testing that use stem cell-derived hepatocyte-like cells.
cell biology,medicine, research & experimental,cell & tissue engineering